Insider Selling: USANA Health Sciences (NYSE:USNA) Insider Sells 4,461 Shares of Stock

USANA Health Sciences, Inc. (NYSE:USNA) insider Joshua Foukas sold 4,461 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $21.34, for a total transaction of $95,197.74. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

USANA Health Sciences Stock Up 0.3%

Shares of NYSE:USNA traded up $0.06 during midday trading on Monday, reaching $21.73. 187,766 shares of the company were exchanged, compared to its average volume of 111,394. The firm has a market cap of $397.22 million, a PE ratio of 39.51, a P/E/G ratio of 0.90 and a beta of 0.67. USANA Health Sciences, Inc. has a fifty-two week low of $18.48 and a fifty-two week high of $38.32. The stock has a fifty day simple moving average of $20.73 and a two-hundred day simple moving average of $23.40.

USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, February 17th. The company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.19. The firm had revenue of $226.20 million during the quarter, compared to analysts’ expectations of $225.96 million. USANA Health Sciences had a return on equity of 6.75% and a net margin of 1.16%. As a group, analysts forecast that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Zacks Research upgraded shares of USANA Health Sciences from a “strong sell” rating to a “hold” rating in a research note on Monday, February 16th. Wall Street Zen raised USANA Health Sciences from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a research note on Monday, December 29th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $36.00.

Institutional Trading of USANA Health Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. State of Tennessee Department of Treasury grew its position in shares of USANA Health Sciences by 307.8% during the 4th quarter. State of Tennessee Department of Treasury now owns 29,290 shares of the company’s stock worth $636,000 after purchasing an additional 22,108 shares in the last quarter. Empowered Funds LLC grew its holdings in USANA Health Sciences by 10.6% during the 4th quarter. Empowered Funds LLC now owns 60,437 shares of the company’s stock worth $1,186,000 after acquiring an additional 5,782 shares during the last quarter. Tudor Investment Corp ET AL grew its holdings in USANA Health Sciences by 354.8% during the 4th quarter. Tudor Investment Corp ET AL now owns 109,686 shares of the company’s stock worth $2,153,000 after acquiring an additional 85,570 shares during the last quarter. Numerai GP LLC acquired a new position in USANA Health Sciences in the 4th quarter valued at approximately $1,027,000. Finally, Millennium Management LLC raised its stake in shares of USANA Health Sciences by 715.7% during the fourth quarter. Millennium Management LLC now owns 285,416 shares of the company’s stock valued at $5,603,000 after acquiring an additional 250,424 shares during the last quarter. Institutional investors and hedge funds own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.